NOVOLIN 70/30
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Jun 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
NOVOLIN 70/30 by Novo Nordisk is insulin, including novolin 70/30, is the regulation of glucose metabolism. Approved for glycemic control in adults. First approved in 1991.
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOVOLIN 70/30 is a human insulin combination product containing 70% NPH (intermediate-acting) and 30% regular (rapid-acting) insulin, approved in 1991. It treats type 1 and type 2 diabetes by replacing or supplementing the body's natural insulin production. The fixed combination provides both basal and bolus coverage in a single injection.
LOE Approaching
As an approaching LOE product, teams are likely in defense/optimization mode with moderate headcount; career growth tied to market share preservation against biosimilars and modern analog competitors.
Mechanism of Action
insulin, including NOVOLIN 70/30, is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein…
Indications (1)
Career Relevance
Working on NOVOLIN 70/30 offers exposure to mature product management and market defense strategy in a competitive insulin market. Career progression is best suited for professionals focused on operational efficiency, pricing strategy, and legacy product optimization rather than innovation.
Worked on NOVOLIN 70/30 at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.